Download Image
    
Share
  
Post
iC1e/K for COVID-19
1 study with 20 patients
Hospital Icon Control Serious Outcome Risk
Hospital Icon iC1e/K
No significant improvements are seen in meta analysis to date.
COVID-19 iC1e/K studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies 0% Mortality 0% RCTs 0% Late 0% FavorsiC1e/K Favorscontrol
Feb 16
2021
 Mansour et al., Viruses, doi:10.3390/v13020309 Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19
no change in mortality (p=1) and 35% lower hospital discharge (p=0.36). RCT 30 severe COVID-19 patients showing no significant difference in mortality or hospitalization time with kinin-kallikrein system inhibitors icatibant or iC1e/K. While there was no impact on mortality or hospitalization time, both treat..